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Abstract 
We previously identified chicken Annexin A2 (chANXA2) as a novel receptor for retrovirus avian leucosis virus sub-
group J (ALV-J), using a DF1 cell line expressing the viral envelope (env) protein. To further probe whether other 
proteins participate in virus infection, we investigated several host proteins from co-immunoprecipitation with the 
DF1 cell line expressing viral env. Mass spectrometry analysis indicates that the chicken glucose-regulation protein 78 
(chGRP78) of the DF1 membrane interacted with the ALV-J env protein. The results revealed that antibodies or siRNA 
to chGRP78 significantly inhibited ALV-J infection and replication, and over-expression of chGRP78 enabled the entry 
of ALV-J into non-susceptible cells. Taken together, these results are the first to report that chGRP78 functions to help 
ALV-J enter cells.
© 2016 The Author(s). This article is distributed under the terms of the Creative Commons Attribution 4.0 International License 
(http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, 
provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, 
and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/
publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
Introduction
Virus infection relies on the interaction between surface 
proteins and host receptors. In addition to virus recep-
tors, other proteins may also interact with the virus and 
mediate infection. For example, HIV, a member of the 
retrovirus family, uses its glycoprotein gp120 to bind with 
CD4, CCR5 and CXCR4 as receptors to infect host cells 
[1–3]. Moreover, certain other proteins, such as CCR1, 
CCR8, CXCR6 (BONZO), GPR15 (BOB), GPR1, APJ, 
CX3CR1 (V28), CXCR5, and RDC1, also interact with 
gp120 and mediate virus entry into host cells [4–10]. 
Some of them were identified as co-receptors, which 
directly interact with virus and facilitate virus invasion to 
susceptible cells with greater efficiency.
ALV is another type of retrovirus. According to the 
antigenicity of its envelope glycoprotein, ALV can be 
divided into six subgroups (A, B, C, D, E, and J). The high 
variability of ALV-J’s envelope (env) protein not only dis-
tinguishes it from other subgroups, but also results in 
alternations of the virus’s pathogenicity, tumourigenicity 
and host range [11]. The env protein’s surface unit (SU) is 
a virus receptor binding-determining region. Currently, 
four cellular receptors for ALV have been identified. Tva 
[12], tvc [13], and chNHE1 [14] interact with the env pro-
teins of ALV-A, C, and J, respectively. Recent research 
has identified chANXA2 as another receptor that is spe-
cific to ALV-J [15]. To further probe whether there are 
other proteins that specifically interact with ALV-J’s env 
protein to mediate viral infection, we used DF1 cell lines 
that over express ALV-J’s env protein to capture proteins 
of interest. Using immunological and molecular biologi-
cal approaches, we identified 78-kDa glucose-regulated 
protein (GRP78) as a novel host protein that interacts 
with the env of ALV-J and is involved in the infection 
of DF1 cells by ALV-J. GRP78 is also referred to as Bip/
HSPA5. This protein consists of membrane-associated 
[16, 17] and trans-membrane segments [18]. More than 
a ER stress-regulating chaperone [19], GRP78 partici-
pates in several biological or immunological processes 
and extensively influences virus infection or pathogenic-
ity [20–23]. Meanwhile, GRP78 has been identified as a 
receptor for different types of virus, such as coxsackie 
B [24] and dengue fever virus [25], which directly inter-
act with viral protein. Our results firmly establish that 
GRP78 can interact with the env of ALV-J to aid the entry 
of ALV-J into cells.
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Materials and methods
Cells and virus
DF1 cells and pcDNA-env_DF1 cells [26] were main-
tained in Dulbecco’s modified Eagle’s medium (DMEM) 
supplemented with 5% fetal bovine serum and 1% antibi-
otics. HEK293T cells and GEF (Goose embryo fibroblast) 
cells were maintained in DMEM supplemented with 10% 
fetal bovine serum and 1% antibiotics. The ALV-J strain 
(JS09GY07) and ALV-A strain (AH10) were preserved in 
our laboratory.
Antibodies and primers
Monoclonal antibody JE9, which specifically recognizes 
ALV-J’s gp85, was employed in the indirect immunofluo-
rescence (IFA), Western blot and immunoprecipitation 
experiments to detect or capture ALV-J’s env protein [27]. 
Monoclonal antibody 5D3, which specifically recognizes 
ALV’s group specific protein p27, was employed in West-
ern blot. A polyclonal antibody for chGRP78 was pur-
chased from Santa Cruz Biotechnology, the product code 
is sc-1051 (Dallas, USA). Monoclonal antibody chicken 
β-actin (Santa Cruz Biotechnology, Dallas, USA) was used 
as an internal control in the Western blot. FITC-labelled 
goat anti-mouse antibody (Sigma, St. Louis, MO, USA) 
and HRP-labelled goat anti-mouse antibody (Sigma) were 
used as secondary antibodies. The primers used in the 
real-time PCR and the siRNA used to inhibit the expres-
sion of chGRP78 are listed in Table 1. The siRNA was syn-
thesized by Invitrogen (Carlsbad, California, USA).
Co‑immunoprecipitation and mass spectrometry
pcDNA-env_DF1 cells in 100 mm dishes were harvested 
by scraping with a rubber policeman and homogenised 
with NP-40 lysis buffer containing 25 mM Tris, 150 mM 
NaCl, 1 mM EDTA, 1% NP-40, 5% glycerol (pH7.4) and 
a protease inhibitor cocktail (Roche, Basel, Switzerland) 
incubating for 20  min, then the membrane proteins in 
the supernatant were sedimented by an additional spin 
at 13 200 g for 1 h at 4 °C and resuspended in 1% NP-40 
lysis buffer. The membrane proteins from the pcDNA-
env_DF1 cells were immunoprecipitated with the mono-
clonal antibody JE9, which is specific to ALV-J Env and 
Resin A (Thermo Scientific, Massachusetts, USA). Pre-
cipitated proteins were separated by SDS-PAGE. The gel 
was stained with a Silver Stain Kit for MS (Thermo Scien-
tific). The bands of interests were collected and analysed 
using mass spectrometry [15].
Antibody blocking assay
The DF1 cells were pre-treated with anti-GRP78 antibody 
which was diluted with DMEM at a concentration of 5, 
25 and 50 μg/mL at 37 °C for 2 h and subsequently chal-
lenged with ALV-J at a MOI of 5 and incubated at 37 °C 
for 2 h. The DF1 cells were pre-treated with anti-GRP78 
antibody which was diluted with DMEM at a concen-
tration of 50  μg/mL and subsequently challenged with 
ALV-A at a MOI of 5 and incubated at 37 °C for 2 h. The 
cells were treated with acid glycine (pH 3.0) for 1 min to 
inactivate the non-internalized virus. After a wash with 
PBS, the cells were maintained in DMEM with 1% foetal 
calf serum and antibody at the concentrations mentioned 
above for 48  h. The replication of ALV-J in the treated 
cells was analysed with IFA, real-time PCR, Tissue cul-
ture infective dose 50 (TCID50) and Western blot, and 
the replication of ALV-A in the treated cells was analysed 
with Western blot.
RNA interference assay
DF1 cells were transfected with stealth siRNA (50 pmol) 
against chGRP78. Six hours later, the cells were infected 
with ALV-J at a MOI of 1 and incubated at 37 °C for 2 h. 
Then, the cells were maintained in DMEM with 1% fetal 
bovine serum for 72  h. The interference effects of the 
siRNA directed against chGRP78 were evaluated with 
real-time PCR. Simultaneously, the replication of ALV-J 
in the DF1 cells was analysed with Western blot and 
TCID50 titration of the ALV-J in the collected cell culture 
supernatant.
Infection of chGRP78‑transfected cells with different 
concentration
First, we inserted the 1982 bp full-length chGRP78 coding 
sequence into pcDNA3.1; human 293T cells were trans-
fected with different concentrations of pcDNA3.1-chGRP78 
(0.5, 1.5, 3.0 and 4.5  μg respectively) and also transfected 
with 4.5 μg pcDNA3.1 as the control. Forty-eight hours later, 
Table 1 Sequences of the primers used for real-time PCR 
and the siRNA against chGRP78
Name Sequence(5′–3′)




Chicken 18s Forward: TCAGATACCGTCGTAGTTCC
Reverse: TTCCGTCAATTCCTTTAAGTT
Human β-actin Forward: CACGAAACTACCTTCAACTCC
Reverse: CATACTCCTGCTTGCTGATC
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the transfected cells were infected with ALV-J at a MOI of 
ten for 2.5 h. Subsequently the cells were treated with acid 
glycine (pH 3.0) for 1 min and washed three times with PBS. 
Then, the 293T cells were maintained in DMEM with 1% 
foetal bovine serum for 48 h. The cells were extracted RNA 
and elevated with real-time PCR.
Infection of chGRP78‑transfected cells
GEF cells were transfected with pcDNA3.1-chGRP78. 
The cells were transfected with pcDNA3.1 as the control. 
Forty-eight hours later, the transfected cells were infected 
with ALV-J at a MOI of ten for 2.5 h. Then, the GEF cells 
were maintained in DMEM with 1% foetal bovine serum. 
After 6 days later, the replication of ALV-J was analysed 
with IFA using JE9 antibody.
Real‑time PCR
RNA was isolated from whole-cell lysates using a Total 
RNA Miniprep Kit (Axygen, California, USA). The RNA 
was reverse transcribed using a PrimerScript RT Reagent 
Kit (Takara, Kusatsu, Japan) with primers targeting the 
ALV-J gp37 and chGRP78 coding sequences. Chicken 
18s and human β-actin were used as an internal control 
in the real-time PCR. Fold change of target gene RNA 
level was calculated with the 2−△△Ct method. GraphPad 
Prism 5.0 (GraphPad Software) was used to analyse the 
data. Data is expressed in column style with mean ± SD 
and statistic variance was analysed using the One-way 
ANOVA test. P < 0.05 was considered as significant.
TCID50 assay
To determine the TCID50 level of the ALV-J in the col-
lected supernatants, DF1 cells were plated in 96-well 
plates (2.5  ×  104 cells/well). Twenty-four hours later, 
the supernatants from antibody blocking assays or RNA 
interference assays were continuously diluted from 10- to 
1010-fold. Each dilution was used to infect the DF1 cells 
in eight duplicate wells. After incubation at 37  °C for 
2.5 h, the supernatants were replaced with DMEM con-
taining 1% foetal bovine serum. Seven days later, the cells 
were immobilized, and IFA was conducted with JE9. The 
final dilution of virus TCID50 was calculated according to 
the Reed-Muench formula.
IFA
The treated DF1 cells and GEF cells were immobilized 
with 4% paraformaldehyde and then treated with 0.25% 
Triton X-100. After incubation with PBS containing 2% 
BSA for 45 min, the cells were incubated with JE9 as the 
primary antibody. Then, FITC-labelled goat anti-mouse 
antibody was used as the secondary antibody. Finally, 
Hoechst 33342 was used to stain the cell nuclei at room 
temperature for 2  min. The cells were stored in 50% 
glycerine, and the fluorescence signals were observed 
under confocal microscopy.
Western blot of env expression in DF1 cells
The expression levels of ALV-J env protein were also 
detected with Western blot. Following infection with 
ALV-J for 48  h, the DF1 cells were harvested and lysed 
with 1% NP-40 and a protease inhibitor cocktail. The cell 
lysates were used for SDS-PAGE and then transferred 
to nitrocellulose membranes for Western blot analysis. 
JE9, 5D3 and β-actin were employed as the first antibody 
respectively, and HRP-labelled goat anti-mouse antibody 
was employed as the second antibody. The membrane 
was finally immersed in Super Signal West Pico (Thermo, 
Massachusetts, USA), and the chemiluminescent signals 
were observed with a FluorChemE imaging system (Pro-
tein Simple, California, USA).
Results
chGRP78 bound the env protein of ALV‑J
To identify a novel ALV-J-binding protein in the DF1 
cells, the pcDNA-env_DF1 cell line expressing ALV-J 
env protein was used in co-immunoprecipitation assays 
(co-IP). The pcDNA-env_DF1 cells were lysed and then 
performed immunoprecipitation with the single mono-
clonal antibody (mAb) JE9, which is specific to ALV-J 
env. Silver staining for SDS-PAGE of the immunoprecipi-
tation revealed several different bands in the lysate that 
was immunoprecipitated with ALV-J-specific mAb JE-9 
and not with the control antibody (Figure 1). Mass spec-
trometry further revealed that one of these bands was 
chGRP78 which was 78-kDa.
The antibody against chGRP78 significantly inhibited ALV‑J 
infection and replication
We used antibodies against chGRP78 to perform block-
ing assays to evaluate the effects of chGRP78 on ALV-J 
Figure 1 Silver staining of the protein precipitates for the 
membrane proteins of the pcDNA-env_DF1 cells. Lane 1, pre-
cipitated with isotype control IgG; lane 2, precipitated with JE9; lane 
3, protein marker.
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infection in DF1 cells. Our results revealed that the viral 
infection/replication of ALV-J was significantly inhib-
ited in groups that had been treated with anti-GRP78. 
As shown in Figure  2A, there was little visible immu-
nofluorescence in the cells that were treated with 50 or 
25  μg/mL of the antibody against chGRP78 in the IFA. 
Moreover, only a few positive cells were found among 
the cells that were treated with 5  mg/mL of antibody 
against chGRP78. In contrast, many positive cells were 
found among the cells that were treated with the control 
IgG and among the untreated cells., the viral titres of the 
cells that were treated with 50 and 25 μg/mL of antibody 
against chGRP78 were approximately 50- and 10-fold 
less, respectively, than those of the cells that were treated 
with the control IgG being consistent with the IFA results 
(Figure 2B). The inhibitory effect on ALV-J infection/rep-
lication conferred by the antibody against chGRP78 was 
also confirmed by Western blot (Figure  2C). As a viral 
control, we also performed a blocking assay for ALV-A 
infection in the DF1 cells. As described in Figure  2D, 
the p27 expression levels of ALV-A in the groups that 
were treated with the antibody against chGRP78 were 
similar to those of the mock group, which indicates that 
the antibody against chGRP78 could not inhibit ALV-A 
infection/replication in DF1 cells. These data clearly 
demonstrate that blocking chGRP78 with a specific anti-
body can effectively and specifically inhibit the infection/
replication of ALV-J.
RNA interference with chGRP78 in DF1 cells inhibited ALV‑J 
infection
To further demonstrate that the chGRP78 protein plays 
an important role in ALV-J infection, an RNA interfer-
ence assay was performed. Three pairs of siRNA were 
employed to reduce chGRP78 expression. Real-time PCR 
indicated that the mRNA level of chGRP78 was signifi-
cantly inhibited in the DF1 cells (Figure  3A). Moreover, 
the Western blot results for the ALV-J envelope protein 
Figure 2 Inhibition of ALV-J infection by antibodies to GRP78. The DF1 cells that had been pre-treated with antibodies against chGRP78 
were infected with ALV-J, and ALV-J replication in the treated cells was analysed. A IFA analysis using JE9; B TCID50 analysis for viral titres; C Western 
blot analysis for the expression of env from ALV-J in the DF1 cells that had been treated with antibodies. Lane 1, blank; lane 2, mock; lane 3, goat IgG 
(50 μg/mL); lane 4, anti-GRP78 (5 μg/mL); lane 5, anti-GRP78 (25 μg/mL); lane 6, anti-GRP78 (50 μg/mL); D Western blot analysis of the expression of 
ALV-A p27 in the DF1 cells treated with antibodies. Lane 1, anti-GRP78 (50 μg/mL); lane 2, goat IgG (50 μg/mL); lane 3, mock.
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and the TCID50 titration of ALV-J in the DF1 cell super-
natant revealed that virus replication was inhibited (Fig-
ures 3B and C). These results suggest that chGRP78 plays 
a significant role in the process of ALV-J infection of the 
host cell.
chGRP78 over‑expression allowed the ALV‑J 
into non‑permissible cells
Human 293T cells, which are non-susceptible to ALV-
J, were transfected with different concentrations of 
pcDNA3.1-chGRP78 (0.5, 1.5, 3.0 and 4.5 μg) respectively, 
and transfected with 4.5  μg pcDNA3.1 as the control. 
After 48 h, the transfected cells were infected with ALV-J 
at an MOI of 5. The viral gp37 gene was detected by real-
time PCR. We found that the mRNA level of ALV-J gp37 
increased apparently with the concentration increasing, 
a significant positive correlation (Figure  4A). To further 
confirm this finding, we also transfected chGRP78 into 
GEF cells in which the ALV-J could not grow [28]. After 
48 h, the transfected GEF were infected with ALV-J. The 
GEF cells were maintained in DMEM medium contain-
ing 1% foetal bovine serum for 6  days. Interestingly, as 
the IFA shows in Figure 4B, virus was recovered from the 
GEF cells transfected with chGRP78, but no virus was 
obtained from the GEF cells that were transfected with 
the control plasmid. Then, the infected GEF and super-
natant were collected to recover ALV-J on DF1 cells. As 
excepted, the virus could be detected on DF1 cells by IFA. 
Figure 3 siRNA against chGRP78 in DF1 cells. The cells were transfected with siRNA (50 pmol) against chGRP78 for 6 h, and the cells were then 
infected with ALV-J at an MOI of 1 for 72 h. A The siRNA effects on chGRP78 were detected with real-time PCR. B The infection/replication of ALV-J 
was analysed with Western blot. Lanes 1, 2, 3 and 4, DF1 cells transfected with siRNA 519, 611, 366 and Mix (co-transfected with 519, 611 and 366), 
respectively, against chGRP78. Lane 5, DF1 cells transfected with control siRNA. C TCID50 analysis of the viral titres.
Figure 4 Infection of the chGRP78-transfected cells. 293T cells 
and GEF cells were transfected with chGRP78, and the transfected 
cells were then infected with ALV-J. A The replication of ALV-J in the 
293T cells transfected with different concentrations of chGRP78 was 
measured by real-time PCR; B The replication of ALV-J in the GEF cells 
transfected with chGRP78 was measured by IFA.
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Together, these data demonstrate that the over-expression 
of chGRP78 in 293T or GEF cells can support ALV-J entry 
into these ALV-J non-permissible cells.
Discussion
Virus attachment and entrance into host cells rely on 
host receptors. Occasionally, other host proteins may 
assist in the virus infection. For example, host glycosa-
minoglycans have been implicated in the mediation of 
the attachment and entry of mosquito-borne flaviviruses 
into mammalian cells [29, 30]; however, the correspond-
ing function has not been elucidated. Previous studies 
with Japanese encephalitis virus (JEV) have reported the 
possible involvements of a 57-kDa protein derived from 
BHK-21 cells, the GAG protein from CHO cells and a 
74-kDa molecule from Vero cells as possible receptors 
[31]. Subsequently, another report hypothesized that 
vimentin, an important cellular protein, is responsible for 
the attachment and entry of JEV into porcine cells [32].
Similarly, in addition to the identified host recep-
tors chANXA2 and chNHE1, we found that chGRP78 
is another important protein for AVL-J infection of 
DF1 cells. chGRP78 is a member of the HSP70 family 
that is located in both the membrane and plasma of 
various types of cells [33]. Despite its immune and bio-
logical functions [34], substantial research has found 
that chGRP78 is a receptor for pathogens such as den-
gue virus [35], coxsackie virus [24] and herpes simplex 
virus [36]. The roles of chGRP78 in the infections of 
other pathogens have been elucidated [37–39]. Collec-
tively, this research indicates that chGRP78 may also 
play a role in avian pathogen infection. In the present 
study, we found that ALV-J replication was significantly 
inhibited when the DF1 cells were blocked with poly-
clonal antibody against chGRP78 or the expression of 
chGRP78 was interfered with via siRNA. The inhibition 
efficiency in DF1 cells is the same as that in chANXA2 
[15]. This finding indicates that chGRP78 may have a 
similar function as chANXA2 in AVL-J infection. The 
over-expression of chGRP78 could permit the entry of 
ALV-J into 293T cells. Our study shows that the RNA 
amount of gp37 was increased in the first 48 h in 293T 
cells which were transfected with chGRP78, while other 
conditions were the same. In addition, ALV-J infection 
efficiency was also dose-dependent on chGRP78 expres-
sion in 293T cells. The gain of ALV-J susceptibility in 
GEF further supports the conclusion that chGRP78 
may be a novel functional co-receptor for ALV-J infec-
tion. This finding indicates the importance of chGRP78 
in AVL-J entry into host cells. However, the potential 
interaction among chNHE1, chANXA2 and chGRP78 
need to be investigated, and the mechanism by which 
chGRP78 introduced ALV-J into the host cells remains 
unclear. Both of these issues are the subject of our 
future research. This research will also provide addi-
tional information regarding retrovirus prevention and 
control.
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